CytoSorbents Announces Strategic Partnership with Fresenius Medical Care Monmouth Junction, N.J.

CytoSorbents Announces Strategic Partnership

with Fresenius Medical Care

Junction, N.J., December 15, 2014 CytoSorbents Corporation (OTCQB: CTSOD), a leader in critical care immunotherapy and

blood purification, announced today that they have entered into a multi-country strategic partnership with Fresenius Medical Care

AG & CO KGaA to commercialize CytoSorbents' CytoSorb therapy.

Under the terms of the agreement, Fresenius

Medical Care will have the exclusive rights to distribute CytoSorb for critical care applications in France, Poland, Sweden,

Denmark, Norway, and Finland. The partnership will allow Fresenius Medical Care to offer an innovative and easy to use blood purification

therapy for removing cytokines in patients that are treated in the intensive care unit.

To promote the success of CytoSorb ,

Fresenius will also engage in the ongoing clinical development of the product. This includes the support and publication of a number

of small case series and patient case reports as well as the potential for future larger, clinical collaborations. This multi-year

agreement is subject to annual minimum guaranteed orders of CytoSorb to maintain exclusivity.

CytoSorb is approved in the European

Union as a safe and effective extracorporeal cytokine adsorber to reduce the excessive production of inflammatory mediators called

cytokines, or "cytokine storm", in life-threatening illnesses such as sepsis and infection, influenza, lung injury,

trauma, burn injury, liver failure, severe acute pancreatitis, and many others. Left unchecked, cytokine storm can lead to massive

deadly whole-body inflammation that can then lead to organ failure, the leading cause of death in the intensive care unit for which

there are no effective therapies. By treating cytokine storm and targeting systemic inflammation, CytoSorb therapy has already

been used safely in thousands of human treatments as a new promising strategy to prevent or treat organ failure, with the potential

to save lives and reduce the tremendous costs of ICU care.

Mr. Christian Schlaeper, Vice President

International Marketing & Medicine, Fresenius Medical Care stated, "We believe CytoSorb has the potential to

transform acute care medicine by providing physicians with an innovative new treatment to manage the harmful inflammatory response

associated with sepsis and other life-threatening illnesses. Together with our leading position in dialysis machines and blood

purification disposables, CytoSorb will strengthen our portfolio of blood purification products. We are pleased to be working

with CytoSorbents to bring this therapy to a greater audience and to achieve excellent patient care for this critically-ill population

and to also reduce healthcare costs.

Dr. Phillip Chan, Chief Executive Officer

and President, CytoSorbents said, "Fresenius Medical Care, as the largest dialysis company in the world, is an ideal

partner to significantly expand the geographic footprint of CytoSorb sales and availability. Fresenius Medical Care has tremendous

resources and people, and an unparalleled distribution network for both acute and chronic dialysis products across the world. This

will enable us to put CytoSorb into the hands of physicians in these countries quickly and help make this unique therapy available

to patients in great need. Along with our existing valued distribution and strategic partners, the total number of countries where

CytoSorb is being marketed increases to 28 worldwide, and is growing. We believe there are many powerful business and competitive

synergies on both sides that can be unlocked through this mutual collaboration and we are thrilled with the prospects."

Mr. Chris Cramer, Vice President of

Business Development, CytoSorbents commented, "We are very excited to begin working with the market leader. Fresenius

Medical Care has made a commitment to the therapy, and will leverage their world-class distribution and marketing capabilities

to help accelerate adoption and usage of CytoSorb and position it as the therapy of choice to help physicians regain control

of their critically-ill patients. Over the coming months, we will work closely with Fresenius Medical Care to ensure a smooth and

successful product launch for CytoSorb . Fresenius Medical Care's commercial network will enable rapid access, education,

training, and support of physicians in some of the largest and most influential hospitals across Europe. The success of CytoSorb

in these countries under this agreement will provide the foundation for future potential expansion together."

There are nearly 130 million people throughout

France, Poland, Finland, and the Scandinavian countries of Sweden, Denmark, and Norway. Citizens in these countries are covered

by universal healthcare funded by the government, but many supplement their healthcare with private insurance. France is the second

largest medical device market in Europe, and spends nearly $300 billion annually on healthcare. Sweden, Denmark, Norway and Finland

are among the highest GDP per capita countries in the world and spend approximately $142 billion on healthcare each year while

Poland spends $36 billion on healthcare annually. According to various epidemiological studies, sepsis and other critical illnesses

account for hundreds of thousands of ICU admissions each year in these territories, at a cost of billions of dollars.

Financial terms of this agreement have

About Fresenius Medical Care

Fresenius Medical Care is the world's largest

integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition

that affects more than 2.5 million individuals worldwide. Through its network of 3,349 dialysis clinics in North America, Europe,

Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 283,135 patients around the globe.

Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related

disposable products.

For more information about Fresenius Medical

Care, visit the company's website at www.fmc-ag.com.

About CytoSorbents Corporation

CytoSorbents Corporation is a critical

care focused immunotherapy company using blood purification to control severe inflammation -- with the goal of preventing or treating

multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive

care unit, with little to improve clinical outcome. CytoSorb , the Company's flagship product, is approved in the European

Union as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise

cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury,

and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb

is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which

can lead to post-operative complications, including multiple organ failure.

purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from

blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based

upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including

HemoDefend , ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website:

http://www.cytosorbents.com/.

Forward-Looking Statements

includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities

Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives,

representations and contentions and are not historical facts and typically are identified by use of terms such as "may,"

"should," "could," "expect," "plan," "anticipate," "believe,"

"estimate," "predict," "potential," "continue" and similar words, although some

forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release

represent management's current judgment and expectations, but our actual results, events and performance could differ materially

from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not

limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2014, as updated by the risks

reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us

from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution

you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise

any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under

the Federal securities laws.